Cancer care - ovarian cancer quality performance indicators review: consultation

11. References

• Scottish Government (2016). Beating Cancer: Ambition and Action Available from: http://www.gov.scot/Resource/0049/00496709.pdf. (accessed December 2016).
• NHS Quality Improvement Scotland (2008) Management of Core Cancer Services Standards. (accessed 5th August 2013).
• Royal College of Pathologists (2010) Datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum (3rd edition). Available from: https://www.rcpath.org/resourceLibrary/g079ovariandatasetnov10-pdf.html (accessed 5th August 2013).
• National Institute for Health and Clinical Excellence (2011) CG122 Ovarian Cancer Update available from: https://www.nice.org.uk/guidance/cg122 (accessed 2nd August 2017).
• SIGN 135: Management of Patients with Epithelial Ovarian Cancer. Update available from: https://www.sign.ac.uk/media/2010/sign135_oct2022.pdf (accessed July 2023)
• Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, 2004 [Cited 2011 Oct 3]; Cancer Care Ontario.. First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Update available from: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/2311 (accessed 17th November 2017)
• SIGN. 2003 [Cited 2011 Oct 3] Epithelial ovarian cancer [online]. (accessed on 5th August 2013); Management of epithelial ovarian cancer. (accessed 17th April 2020).
• Australian Cancer Network (2004) Clinical practice guidelines for the management of women with epithelial ovarian cancer. Available from: https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/clinical-practice-guidelines-management-women-epithelial-ovarian-cancer (accessed 5th August 2013).
• Miller RE et al ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. PMID: 33004253.
• NHS Quality Improvement Scotland (2008). Management of Bowel Cancer Services Standards [online]. (accessed October 2012).
• SOLO 1 - Moore et al. Maintenance olaparib in patents with newly diganosed advanced ovarian cancer. N Engl J Med 2018; 379:2495-2505.
• PAOLA/ENGOT Ov25 - Ray-Coquard et al. Olaparib plus bevacizumab as first line maintenance in ovarian cancer. A phase 3 trial of bevacizumab in ovarian cancer. Lancet 2011. Perren et al. NEJM 2011;365:2484-2496.
• Vergote, I., Coens, C., Nankivell, M., Kristensen, G.B., Parmar, M.K., Ehlen, T., Jayson, G.C., Johnson, N., Swart, A.M., Verheijen, R. and McCluggage, W.G., 2018. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology, 19(12), pp.1680-1687.
• Fagotti, A., Ferrandina, M.G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P.A., Chiantera, V., Costantini, B., Alletti, S.G. and Cosentino, F., 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecologic Cancer, 30(11).
• Yao, S.E., Tripcony, L., Sanday, K., Robertson, J., Perrin, L., Chetty, N., Land, R., Garrett, A., Obermair, A., Nascimento, M. and Tang, A., 2020. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. International Journal of Gynecologic Cancer, 30(12).
• Plett, H., Filippova, O.T., Garbi, A., Kommoss, S., Rosendahl, M., Langstraat, C., Phadnis, S., Muallem, M.Z., Baert, T., Chi, D.S. and Aletti, G.D., 2020. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecologic oncology, 159(2), pp.434-441.
• Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B,Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 182(18), E839-E842 (online). Available from: http://www.cmaj.ca/content/182/18/E839.full.pdf+html?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=brouwers&searchid=1&FIRSTINDEX=0&volume=182&issue=18&resourcetype=HWCIT%2520%2520%2520 (accessed August 2013)